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Embryonic stem (ES) cells have the ability to reproduce themselves for a long period and differentiate into specific 
morphological and functional cells. The ES cells are an important material in developmental biology, genomics, and 
transgenic methods, as well as in potential clinical applications, gene therapy and tissue engineering. The pluripotent ES 
cells will be a valuable source in the treatment of numerous functional degenerative pathologies including Parkinson’s 
disease (PD), which is characterized by progressive and selective loss of dopaminergic neurons in the midbrain substan-
tia nigra. Thus, the most important for using ES cells in PD therapy is to direct their differentiation into dopaminergic 
phenotype to replace the degenerated cells. In this review, we summarize the neural differentiation directing protocol, 
transplantation results, and behavioral recovery of ES cells derived dopaminergic neurons in the therapeutic studies 
in PD animal models.
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Introduction
Mammalian stem cells have the ability to prolongate 
proliferation and differentiate into several special-
ized cells that make up the tissues and organs of the 
body. Stem cells are classified by their sources into 
three classes: the embryonic stem (ES) cells that are 
derived from the inner cell mass of preimplantation 
blastocyst,1−3 the embryonic germ cells that are de-
rived from the primordial germ cells of the primitive 
genital ridge in the fetus,4,5 and the adult stem 
cells that are isolated from differentiated tissues 
such as bone marrow, brain, blood, liver, pancreas, 
and skin.6−8 The ES cells are believed to be most 
pluripotent, and under certain specific conditions, 
ES cells can give rise into cells of all three primary 
germ layers, ectoderm, mesoderm, and endoderm. 
Research in this area opens a new window into the 
embryonic developmental biology.9 Consequently, 
the pluripotency of ES cells will be a valuable source 
of cell replacement therapy in numerous pathologies 
and has the potential to be used in cell transplan-
tation and biomedical engineering.10,11
Many mammalian ES cells were derived in last 3 
decades, including mouse,1 human,3 rabbit,12 rat,13 
rhesus monkey,14 marmoset,15 pig,16,17 and some 
presumptive pluripotent ES cells, including ham-
ster,18 sheep,19 cattle,20 and mink.21 Research in 
establishing committed tissue-specific progenitors 
from ES cells and evidence of their function after 
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transplantation in various animal disease models are 
also reviewed.22 The ES cells can serve as important 
tools in developmental biology, genomics, and trans-
genic methods, as well as in potential clinical appli-
cations such as degenerative medicine, traumatic 
disorder, gene therapy and tissue engineering.23,24
Differences Between Human, 
Porcine and Murine ES Cells
Research has had remarkable results in inducing 
human ES cells differentiation into neuronal cells,25,26 
pancreatic β cells,27 and cardiomyocytes.28 These 
results reveal the potential for the clinical applica-
tion of human ES cells for the treatment of diseases 
such as spinal cord injury,29 Parkinson’s disease 
(PD),30 diabetes,31 and heart diseases.32 Although 
human ES cells hold a promising future for treating 
degenerative disorders such as Parkinson’s and 
Alzheimer disease, or in treating spinal cord injury, 
the preclinical research must be proven in suitable 
animal models to present its bio-safety and long-
term efficiency of transplanted ES cells and/or their 
derived cells. Studies demonstrate the existence of 
differences between human ES and murine ES cells, 
suggesting that the information gained from murine 
ES cells, especially the gene expression profiles 
during neural differentiation, cannot be directly 
translated to human ES cells.17,33 Swine has been 
demonstrated as an excellent animal model in ther-
apeutics development for various human diseases, 
including congenital heart disease,34 hypertension,35 
organ transplantation,36,37 pharmacology, and toxi-
cology.38,39 In addition, the colony morphology of 
the porcine ES cells are very similar to human ES, 
and they are both feeder-dependent and refractory 
to leukemia inhibit factor. Porcine ES cells cluster 
into colonies sharing a flattened morphology of 
human ES but not mouse ES cells.16 They both ex-
press octamer-binding transcription factor-4 (Oct-4), 
alkaline phosphatase (AP), stage specific embry-
onic antigen-3/4 (SSEA-3/4), tumor related antigen 
(TRA) 1-60, and TRA 1-81, but not the SSEA1 that is 
characterized by mouse ES cells.40 Therefore, the 
porcine ES cells can provide an optimal preclinical 
animal model in the study of regenerative medi-
cine in therapeutic approaches.
Parkinson’s Disease and 
Animal Research Models
PD is a degenerative disorder that was first de-
scribed by Dr. James Parkinson in 1817. The PD pa-
tients show shaking rigidity, balance problems and 
slowed movement in behavioral symptoms. Several 
major medical approaches of PD therapy, including 
pharmacological therapy with the dopamine precur-
sors such as L-3,4-dihydroxyphenylalanine (L-dopa), 
Carbidopa-Levodopa (Sinemet) and Selegiline hydro-
chloride (Eldepryl). This DA-replacement treatment 
takes effects during early stages but is associated 
with devastating side effects, such as dyskenesia.41 
Further more, implanted Deep Brain Stimulation in 
subthalamic nucleus to stimulate with tiny electri-
cal current can reduce the abnormal movement of 
PD patient.42 Another surgical approach is to trans-
plant fetal ventral mesencephalic cells in PD pa-
tients.43 However, fetal cells transplantation has 
limitations with technical and ethical issues.44 Due 
to the self-renewal capacity and multilineage de-
velopmental potential, ES cells can be ideal cell 
sources for cell replacement therapy.45,46
For the ES cells transplantation and functional 
recovery studies of PD, the nigrostriatal lesion and 
amphetamine-induced rotation behavioral analyses 
are well developed. The 6-hydroxy dopamine (6-
OHDA) is injected into the medial forebrain bundle 
(nigrostriatal dopaminergic pathway) with the 
assistance of a stereotaxic instrument (anterior-
posterior, AP = −4.4 mm; medial-lateral, ML = −1.2 mm; 
dorsal-ventral, DV = −7.8 mm; and AP = −4.0 mm, 
ML = −0.8 mm, DV = −8.0 mm).47,48 After lesioning, 
the animals demonstrate asymmetric rotations by 
using an automated rotometer (TSE, Germany)49,50 
in response to D-amphetamine challenge are char-
acterized as well-lesioned PD models and are used 
for ES cells transplantation into the striatum 
(AP = 0.0 mm, ML = −3.0 mm, DV = −5.0 mm).48
Neural Induction of ES cells
The efficiency for neural population conversion is 
the most important for stem cell replacement ther-
apy in the field of neurological disorders. Although 
the low efficiency of neural differentiation derived 
from ES cells has been one of the major obstacles 
to overcome,51 a significant improvement of neural 
lineages induction has been achieved by applica-
tion of several morphogens such as all-trans retinoic 
acid (RA), sonic hedgehog (SHH), fibroblast growth 
factor (FGF), epidermal growth factor (EGF), bone 
morphogentic proteins (BMPs), and glial-derived 
neurotrophic factor (GDNF).52−58 These molecules 
are essential for normal embryonic development 
and differentiation,59 and are used as neurogenic 
stimulators of ES cells.26,55,60 Perrier et al57 devel-
ops an in vitro neural induction protocol of hES-
derived dopaminergic differentiation by co-culture 
with stromal cells MS5 and S2. A similar protocol also 
reports using co-culture with PA6 stromal cells61 and 
PA6 cells overexpressing PA6-SHH.62 A rapid protocol 
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using the chemically defined culture system also 
allows human ES cells to differentiate into DA neu-
rons by the addition of SHH and FGF-8,63 or the 
recombinant human noggin, bFGF and dibutyryl-
cAMP,64 or FGF8b and SHH.65 Those derived cells 
exhibit the specific dopaminergic markers such as 
Lmx-1b (a transcription factor regulated the de-
velopment of midbrain DA neurons), Nurr-1 and 
Ptx-3 (transcription factors expressed in midbrain 
DA neurons), Girk2 (a potassium channel expressed 
specific to DA neurons in the substantia nigra) and 
TH (a biosynthetic enzyme of DA).62,64−66 These suc-
cessful induction protocols provide powerful tools 
to control the development and function of ES-
derived midbrian DA neurons and makes ES cell 
therapy on PD promising in the future.
Porcine ES Cells in PD Therapy
In our laboratory, we establish a porcine ES cell line 
M215-3 derived from the blastocyst of the Livestock 
Research Institute Black Pig No. 1 (a topcrossing 
breed established from Taoyuan and Duroc pigs) 
(Figure 1); we also derived three GFP-expressing 
ES cell lines from M215-3 by electroporation desig-
nated as pES/GFP+ 10, 14-1, and 14-2 (Figure 2).40 
They all maintain normal karyotype of 36 + XX and 
express the pluripotent markers Oct-4, AP, SSEA-3, 
SSEA-4, TRA 1-60, and TRA 1-81. For the study on 
ES cell therapy in neural regenerative disorders, 
we develop a directed differentiation protocol in-
cluding a neural induction culture for 12 days and 
extending culture for 6 days. This induction allows 
us to attain more differentiated neural lineages 
that also provide a valuable yield on the process of 
differentiation of porcine ES cells into functional 
neurons (Figure 3). Furthermore, the pigs offered 
some distinct advantages over other species and 
served as a better research model because they 
were immunologically and physiologically more sim-
ilar to humans. This directed induction protocol 
will be helpful in further application of porcine ES 
cells in replacement medicine and in numerous func-
tional degenerative pathologies. In our studies, we 
presented an in situ monitoring of these grafted cells 
with the assistance of a stereotaxic instrument, and 
their survival and development was determined every 
15 days by two of live animal fluorescence optical 
imaging systems: the In Vivo Imaging System (IVIS 
50; Xenogen Corp., Alameda, CA) was for the nonin-
vasive tracking (Figure 4), and the real-time images 
of grafted cells in recipient’s brain was performed 
by ex vivo fibered confocal Cellvizio Imaging System 
(Cellvizio, Mauna Kea Technologies, Cambridge, MA, 
Figure 1 The colony morphology of porcine embryonic 
stem cells M-215-3.
Figure 2 The colony morphology of porcine embryonic 
stem cells expressing green fluorescent protein (pES/
GFP+ 10).
Figure 3 The porcine embryonic stem cell–derived neu-
ral cells showed a typical neural morphology with cell 
body and axons after directed differentiation.
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USA) for invasive tracking during the 3 months of 
experimental period (Figure 5). We also injected 
pES/GFP+ cells and their derived cells of neural 
differentiation stages into the 6-OHDA lesioned PD 
rats. The in vivo cell growth and differentiation of 
the grafted cells, and the functional recovery of the 
PD animals were investigated in our study.48
However, a major concern of ES transplantation 
is the tumorgenic potential if ES cells are to be 
applied clinically.67 Consequently, the effort to de-
termine those ES-differentiated cells posttrans-
plantation in vivo aimed at monitoring the survival 
and development of grafted ES or ES-derived cells 
in PD therapy. The need for noninvasive or invasive 
monitoring of model systems has resulted in the 
development of small animal imaging technologies 
such as microcomputed tomography, micropositron 
emission tomography, magnetic resonance imag-
ing,68,69 or fluorescence cystoscopy with hexyl ami-
nolevulinate,70 optical coherence tomography,71 
positron emission tomography,72 and fibered con-
focal microscopy.73 All of which are now capable of 
providing real-time images and obtaining the fate 
of ES cells for therapeutic purposes,72,74,75 the course 
of cancer metastasis and therapy,69,76,77 and embryo 
development.78
To investigate the therapeutic potential in PD, 
we transplanted porcine ES cells into the Sprague-
Dawley rat brain with the assistance of a stereo-
taxic instrument. Following 3 month of behavioral 
analyses after porcine ES cells transplantation, the 
functional behavior recovery analysis by ampheta-
mine-induced rotation test indicated the grafted 
porcine ES-derived neuronal progenitors showed a 
decreased relative rotation rate and resulted in a 
functional recovery from PD behavioral defects.48 
The results of our study and several previous studies 
on PD therapy in the animal models are summarized 
in Table 1.45,46,48,61,62,65,67,72,79−92 Several studies in-
dicate that the grafting of mouse or human ES-
derived DA neurons can reduce functional deficits 
significantly in PD animal models.45,46,48,79,80−86 
How ever, some studies show partial recovery from 
Total:  Area flux = 6.989 × 108
GIM20070411092301 – GIM20070411092220 * 2
Image
Min = −5.899 × 107
Max = 2.0919 × 107
p/sec/cm2/sr
Color bar
Min = 7 × 106
Max = 2 × 107











Figure 4 Evaluation of the fluorescence intensity of grafted pES/GFP+ cells. Images were monitored with the contin-
ued tracking of the same rats with In Vivo Imaging System (IVIS) 50 for 3 months. (Left: control; Right: treatment). 
ROI: region of interest.
40 μm
Figure 5 The real-time image of grafted pES/GFP+ 
cells in recipient’s brain was determined by using ex 
vivo fibered confocal Cellvizio Imaging System.
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behavioral defects through the grafted mouse or 
monkey ES-derived cells.72,87 Some studies even 
show failure in improving rotational behavior defi-
cits when animals were transplanted with human ES-
derived dopaminergic cells.62,67,88 These inconsistent 
results imply the cell purification, cell population, 
induction protocol, survival and functional exhibition 
of grafted DA neurons are crucial for PD therapy.48 
The ES cell transplantation in the animal model of PD 
proves that this method is capable of relieving symp-
toms and offers real approach for cell replacement 
in regenerative diseases in the future.
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